Table 1.
Baseline characteristics of all patients with advanced esophageal cancer who received or did not receive chemotherapy
|
Variable
|
All patients (n = 29182)
|
Chemotherapy received (n = 21911)
|
No chemo received (n = 7271)
|
| Age | |||
| Median (IQR) | 64 (56-73) | 63 (55-71) | 69 (59-79) |
| Gender | |||
| Female | 5126 (17.57) | 3569 (16.29) | 1557 (21.41) |
| Male | 24056 (82.43) | 18342 (83.71) | 5714 (78.59) |
| Race | |||
| Black | 2878 (9.95) | 1936 (8.9) | 942 (13.12) |
| Other | 1669 (5.77) | 1245 (5.72) | 424 (5.9) |
| White | 24389 (84.29) | 18574 (85.38) | 5815 (80.98) |
| Insurance type | |||
| Medicaid | 2415 (8.44) | 1752 (8.14) | 663 (9.36) |
| Medicare | 13412 (46.87) | 9263 (43.02) | 4149 (58.58) |
| Not insured | 1404 (4.91) | 959 (4.45) | 445 (6.28) |
| Other government | 459 (1.6) | 323 (1.5) | 136 (1.92) |
| Private | 10923 (38.17) | 9233 (42.88) | 1690 (23.86) |
| Income quartiles for place of residence | |||
| Less than $30000 | 3918 (13.99) | 2687 (12.79) | 1231 (17.61) |
| $30000-$34999 | 5362 (19.15) | 3942 (18.77) | 1420 (20.31) |
| $35000-$45999 | 8066 (28.81) | 6081 (28.95) | 1985 (28.39) |
| $46000+ | 10652 (38.05) | 8297 (39.5) | 2355 (33.69) |
| Treatment site | |||
| Academic | 12955 (45.07) | 9856 (45.75) | 3099 (43.05) |
| Non-academic | 15786 (54.93) | 11686 (54.25) | 4100 (56.95) |
| Geographic location in United States | |||
| Midwest | 8278 (28.8) | 6388 (29.65) | 1890 (26.25) |
| Northeast | 6772 (23.56) | 5178 (24.04) | 1594 (22.14) |
| South | 9509 (33.09) | 6977 (32.39) | 2532 (35.17) |
| West | 4182 (14.55) | 2999 (13.92) | 1183 (16.43) |
| Residence area type | |||
| Metro | 22465 (80.15) | 16883 (80.25) | 5582 (79.88) |
| Rural | 641 (2.29) | 467 (2.22) | 174 (2.49) |
| Urban | 4921 (17.56) | 3689 (17.53) | 1232 (17.63) |
| Number of comorbidities1 | |||
| 0 | 22009 (75.42) | 17017 (77.66) | 4992 (68.66) |
| 1 | 5401 (18.51) | 3789 (17.29) | 1612 (22.17) |
| ≥ 2 | 1772 (6.07) | 1105 (5.04) | 667 (9.17) |
| Year of diagnosis | |||
| 2004-2009 | 15715 (53.85) | 11588 (52.89) | 4127 (56.76) |
| 2010-2014 | 13467 (46.15) | 10323 (47.11) | 3144 (43.24) |
| Grade2 | |||
| 1 | 633 (2.77) | 475 (2.73) | 158 (2.89) |
| 2 | 7926 (34.65) | 6099 (35.02) | 1827 (33.46) |
| 3 | 13849 (60.54) | 10497 (60.28) | 3352 (61.38) |
| 4 | 467 (2.04) | 343 (1.97) | 124 (2.27) |
| AJCC T stage | |||
| T0 | 51 (0.32) | 31 (0.24) | 20 (0.58) |
| T1 | 2624 (16.26) | 1889 (14.86) | 735 (21.45) |
| T2 | 1751 (10.85) | 1442 (11.35) | 309 (9.02) |
| T3 | 7128 (44.18) | 6105 (48.04) | 1023 (29.86) |
| T4 | 4570 (28.33) | 3233 (25.44) | 1337 (39.03) |
| pIS | 10 (0.06) | 8 (0.06) | 2 (0.06) |
| AJCC N stage | |||
| Negative | 4983 (22.23) | 3562 (20.36) | 1421 (28.86) |
| Positive | 17435 (77.77) | 13933 (79.64) | 3502 (71.14) |
1
Per Charlson/Deyo[11].
2
Grade 1, well-differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated; grade 4, undifferentiated.
Data are presented as number of patients (column %) or median (interquartile range). AJCC: American Joint Committee on Cancer.